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1. Introduction
1.1. TP53 Mutations and CNS tumors
Central nervous systems (CNS) malignancies, as others cancers, are formed by the uncontrol‐
led cell growth that involves the sequential accumulation of alterations in genes controlling
cell proliferation, lifespan, responses to stress, relationships with neighbors, and gene homeo‐
stasis. These genetic alterations can be achieved by intragenic mutations, chromosome
alterations or epigenetics modifications, all playing important role in the activation or
inactivation of key genes, such as oncogenes and tumor suppressor genes. Some of these
mutations can be most frequently encountered in specific cancers or group of cancers and
correlated with tumor biologic behavior and have implications on diagnosis, prognosis or
treatment [1].
Biomarkers are important oncology tools in diagnostic, monitoring disease progression,
helping in determining prognosis and predicting therapeutic response. Biomarkers vary from
specific proteins and antigens to unique genetic, epigenetic or cytogenetic profiles, but common
to all markers is that they provide specific information to a disease process. They function as
supplementary and rarely supplanting, the histopathologic examination of tissues that is still
the mainstay of traditional oncologic pathology [2, 3]. For this reason, we intend to compile
the vast information about the important contribution of TP53 gene as a biomarker in CNS
cancer genesis, progression, stratification, prognosis, treatment and its importance to future
targeted therapies.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
CNS cancers are heterogeneous diseases, arbitrarily grouped by the systems that are affected.
The “WHO (World Health Organization) Classification of Tumors of the Central Nervous
System” discriminates more than one hundred different diseases derived from different cell
types, affecting patients of different ages, with a vast biological behavior and clinical implica‐
tions. It is not our intention to describe the features of each CNS tumor. Hence, authors will
follow the WHO classification for CNS tumors [4].
TP53 tumor suppressor gene is the most frequently mutated gene in human tumors and one
of the most studied on different kinds of cancer. It is a large and complex gene located on
chromosome site 17p13.1 (Figure 1). It has 11 exons along approximately 20.000bp. This gene
codifies a protein with 393 amino acids in which different domains are responsible for diverse
functions as exhibited on Figure 1. Genetic variations in this gene contribute to human cancers
in many different ways. Firstly, somatic mutations are frequent in most cancers [5]: it is
estimated that mutations in this gene are present in half of the human cancers. The antiproli‐
ferative role of p53 protein in response to various stresses and during physiological processes
such as senescence makes it a primary target for inactivation [6], mainly by a combination of
single-base substitution and loss of alleles [7]. Secondly, inheritance of a mutated TP53 causes
predisposition to early-onset cancers including breast carcinomas, sarcomas, brain tumors,
and adrenal cortical carcinomas, defining the Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL)
syndromes [8, 9]. Thirdly, TP53 is highly polymorphic in coding and noncoding regions and
some of these polymorphisms have been shown to increase cancer susceptibility and to modify
cancer phenotypes in TP53 mutation carriers [10].
Commonly, advanced stage or aggressive behavior cancers have a higher frequency of TP53
mutations [11, 12]. Moreover, in cancers with low mutation rates, p53 is often inactivated by
alternative mechanisms, like protein degradation. TP53 allelic deletion is also observed in
many tumors, resulting in the reduction of expression of tetramers and decreased expression
of genes inhibiting cell growth [13]. The cancer-associated somatic mutations in TP53 are
primarily missense substitutions (72.28%) nonrandomly distributed along the molecule, [14].
Over 90% of p53 mutations occur in the central DNA-binding-domain (Figure 1) into exons 4
– 9. These single aminoacid changes affect the transcriptional activity of the gene to various
degrees; sometimes missense mutants may even acquire new functions [15, 16]. The TP53
mutational pattern has proved to be a clinically relevant “molecular sensor” of genotoxic
exposure to environmental carcinogens and endogenous mutagens [17].
Among single-base substitutions, about 25% are C:G>T:A substitutions at CpG sites. CpG
dinucleotides mutate at a rate 10 times higher than other nucleotides, generating transitions
[18]. About 3%–5% of cytosines in the human genome are methylated at position 5’ by a
postreplicative mechanism that is restricted to CpG dinucleotides and is catalyzed by DNA
methyltransferases. The 5’ methylcytosine (5mC) is less stable than cytosine and undergoes
spontaneous deamination into thymine at a rate five times higher than the unmethylated base.
This process is enhanced by oxygen and nitrogen radicals, leading to a higher load of CpG
transitions in cancers arising from inflammatory precursors such as Barrett’s mucosa or
ulcerative colitis [19, 20]. Among the 22 CpG of the DNA-binding domain (DBD), three hotspot
codons (175, 248, and 273) represent 60% of CpG mutations and another five residues (196, 213,
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245, 282, and 306) account for 26% of these mutations. The lack of mutations at other CpG sites
may reflect the fact that substitutions at these residues do not generate a dysfunctional protein.
Although the same CpG hotspot mutations occur in many cancer types, other types of
mutations tend to show differences among different cancers. Some of these differences have
been linked to the effect of specific mutagens. This idea is endorsed by geographic differences
which can be related to different environmental exposures [21].
All these mutational information about TP53 are compiled in the International Agency for
Research on Cancer (IARC) TP53 Database [14], which provides structured data and analysis
tools to study TP53 mutations for specific cancers or investigate the functional and clinical
impact of some mutations. The existence of this database, dedicated to annotate TP53
mutations, polymorphism and respective implications in clinical and pathological behavior of
human cancers, demonstrates the importance and the necessity of more knowledge to
complete understand its implication on cancer [22].
Several studies have investigated the predictive value of TP53 mutation status for tumor
response to treatment and patient outcome in various cancers. However, different clinical and
methodological settings have been used and the results have often been heterogeneous and
contradictory [22]. The number and complexity of pathways in which TP53 participates, the
different mutational profiles of each cancer and the diverse environment conditions are
variables that can contribute to these heterogeneous results.
Figure 1. TP53 gene: Structure, chromosome localization and protein domains distribution. TP53 is mapped on hu‐
man chromosome site 17p13.1. It is a long gene, with 19, 149 base pair comprising 11 exons that codify a protein with
393 amino acids long, in which the transactivation, proline-rich, DNA binding and the oligomerization domains are
distributed. There are nuclear export/localization signals inside and between some domains (NES/NLS).
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The majority of mutations led to protein accumulation in the nucleus of the cells, which can
be detected by immunohistochemistry (IHC) assays. Although some studies have shown an
association between p53 positive immunostaining and poor outcomes, several studies have
produced conflicting results and expectations on the use of p53 as a useful clinical biomarker
failed [23]. Therefore, it seems IHC is a poor surrogate for gene mutation detection, as many
mutations do not lead to protein accumulation, and because accumulation of wild-type p53
may also occur in the absence of gene mutation, producing a high rate of false negative and
positive results. Hence, the use of IHC leads to an unacceptable number of misclassified cases
and to a greater inter-study variability [1, 22].
By contrast, the screening for TP53 mutations by gene sequencing, precisely identifying the
mutation, have produced more consistent results, at least for some types of cancers such as
breast, head and neck squamous cell carcinoma (HNSCC), and leukemia, in which the presence
of a TP53 mutation is associated with poor outcomes. In other types of cancer such as brain
and pancreas, mutations were also found to be associated with both poor and good prognosis,
depending on the study and cancer. These results show that the type of tissue and treatment
may be important determinants of the prognostic and predictive value of TP53 mutations [1,
22]. Figure 2 illustrates the use of different techniques in the evaluation of mutational status
of TP53 and expression of p53 protein in gliomas. Fluorescence in Situ Hybridization (FISH),
sequencing and IHC techniques.
2. TP53 genetic alterations in CNS tumors
CNS tumors have historically been classified on the basis of morphological and, more recently,
immunohistochemical features with less emphasis on their underlying molecular pathogene‐
sis. The past two decades, however, have seen striking advances in basic brain tumor biology,
especially with regard to malignant gliomas and medulloblastomas, the most common CNS
cancers of adults and children, respectively [24, 25]. Molecular signatures of tumors may play
roles as diagnostic, prognostic, and predictive markers and influence the clinical decision
making process. A dynamic classification of tumors is critical for the continuous integration
of newly established molecular tools. This topic focuses on various genetics and epigenetics
TP53 changes in the CNS tumors which have been integrated into daily practice and gained
significance for molecular diagnostic testing. Detailed discussion of neuronal and mixed
neuronal-glial tumors, tumors of the pineal region, tumors of cranial and paraspinal nerves,
mesenchymal tumors, lymphomas and haematopoietic neoplasms and other tumor entities is
beyond the scope of this chapter, especially because there is only limited molecular information
used in clinical management available for this types of tumors.
2.1. Gliomas
Gliomas are the most frequent primary brain tumors and include a variety of different
histological types and malignancy grades. Although the cellular origin of gliomas is still
unknown, experimental data in mice suggest an origin from neoplastically transformed neural
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Figure 2. Different approaches used in the analysis of TP53 gene in gliomas. (A) and (B) FISH experiments using TP53
locus specific probe (red) and 17 centromeric probe (green) in metaphase chromosomes. A normal pair of chromo‐
some 17 is showed in (A), while a heterozygous deletion of TP53 can be observed in (B). (C) Immunopositive p53 sam‐
ple, demonstrated by immunohistochemical staining. (D) Electropherogram of an patient with the wild type sequence
(CGC) in the codon 72 while (E) illustrates a base exchange mutation in this position (CCC) predicting de aminoacid
substitution arginine → proline.
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stem or progenitor cells. However, histological classification of gliomas essentially relies on
morphological similarities of the tumor cells with non-neoplastic glial cells and the presence
of particular architectural features; thereby, most gliomas can be classified as astrocytic,
oligodendroglial, mixed oligoastrocytic or ependymal tumors according to the criteria of the
WHO classification of CNS tumors [4]. Clinical experiences derived from the prospective
randomized clinical trials have shown that the histomorphological criteria alone might not be
sufficient to predict the clinical outcome. Moreover, lately integrated genomic studies and
exome sequencing have revealed the existence of multiple distinct molecular subtypes within
histologically similar looking tumors [26]. For instance, even gliomas with identical histopa‐
thological features differ considerably regarding clinical course or response to therapy.
Knowledge of the genetic alterations in the various types and malignancy grades of gliomas
has drastically increased over the past years. The evolution of classical tumor molecular and
cytogenetic techniques, as well as the development of newer array-based assays of compara‐
tive genomic hybridization and RNA expression, allowed subclasses of gliomas to be identified
based on molecular or gene expression patterns, showing substantial genetic and gene-
expression heterogeneity within and between histologic grades of different histologic types of
gliomas [27]. These approaches have identified point mutations and copy number changes
(deletions, amplifications, gains) in several regions; deletions and loss of heterozygosity in
tumors might point to genes involved in tumor suppression, whereas amplifications and gains
might point to genes involved in initiation or progression processes (e.g. oncogenes) [28].
Numerous molecular abnormalities have been associated to the underlying biology of gliomas.
The p53 pathway is nearly invariably altered in sporadic gliomas: loss of p53, through either
point mutations that prevent DNA binding or deletion in chromosome 17p, is a frequent and
early event in the pathological progression of secondary glioblastoma (GBM) [29, 30]. The
importance of p53 in gliomagenesis is also underscored by the increased incidence of gliomas
in LFS, a familial cancer-predisposition syndrome associated with germline p53 mutations [31].
This genetic linkage has been reinforced by a glioma-prone condition in mice engineered with
a commonly observed Li-Fraumeni p53 mutation [32] as well as in p19ARF-null mice, albeit at
a low frequency [33]. In human gliomas, p53 mutations are primarily missense mutations and
target the evolutionarily conserved domains in exons 5, 7, and 8, thus affecting residues that
are crucial to DNA binding [30].
The finding that a second promoter drives an alternatively spliced transcript at the CDKN2A
locus prompted the discovery of an additional tumor suppressor gene that is inactivated at
this locus [34]. The second protein encoded by CDKN2A, p14 ARF, was subsequently shown to
be an important accessory to p53 activation under conditions of oncogenic stress due to its
neutralization of the p53 ubiquitin ligase, MDM2 [35, 36], an oncogene originally discovered
amplified as double minute chromosomes in a spontaneously transformed murine cell line,
and then later found to be a key negative regulator of p53 during normal development and in
tumorigenesis [37-39]. Concordantly, the chromosomal region containing MDM2, 12q14-15, is
amplified in ∼10% of primary GBM, the majority of which contain intact p53 [40]. The
discovery of the MDM2-related gene, MDM4 (chromosome 1q32), which inhibits p53 tran‐
scription and enhances the ubiquitin ligase activity of MDM2, prompted the finding that the
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p53 pathway is also inactivated by the amplification of MDM4 in 4% of GBM with neither TP53
mutation nor MDM2 amplification [41, 42]. Additionally, the recently discovered tumor
suppressor gene CHD5 (chromodomain helicase DNA-binding domain 5), which maps to
chromosome 1p36 and is therefore frequently hemizygously deleted in those human gliomas
with loss of 1p, has been shown to maintain p53 levels by facilitating expression of p19 Arf
(mouse p14ARF ortholog), and thus presents an additional mechanism for inactivation of this
critical pathway [43].
2.1.1. Astrocytic tumors
The incidence of TP53 mutations in pilocytic astrocytomas is controversial, with some authors
reporting only infrequent mutations [44-47], while more common mutations are rare [48].
Hayes et al. [48], were the first to find a higher rate of TP53 mutations in an analysis of 20
pilocytic astrocytomas in children, based on a comprehensive denaturing gradient gel
electrophoresis mutation detection assay of the entire coding region, including all splice site
junctions of TP53, showed mutations considered as causative in 7 of the 20 (35%) pilocytic
astrocytomas. Few Cytogenetic studies have been carried out, showing allelic losses on both
17p and 17q including the TP53 and NF1 loci in pilocytic astrocytomas [49]. These results
suggest that TP53 mutations may well play a role in the development of these tumors.
TP53 mutations are a genetic hallmark of low-grade diffuse astrocytomas, for > 60% of these
tumors carrying mutations in this gene [47, 50], mainly in gemistocytic astrocytomas with TP53
mutations in up to 80% of the cases [51, 52]. In most cases, TP53 mutation is accompanied by
loss of heterozygosity (LOH) on 17p resulting in the complete absence of the wild-type TP53
gene. Those diffuse astrocytomas with no TP53 mutations may have altered the p53-dependent
growth control by alternative mechanisms, for example, promotor methylation of the p14 ARF
gene at 9p21. Nakamura et al. [53] found hypermethylation of p14ARF in one third of low-grade
diffuse astrocytomas samples. These results suggest that aberrant p14ARF expression due to
homozygous deletion or promoter hypermethylation is associated with the evolution of both
primary and secondary GBMs, and that p14ARF promoter methylation is an early event in subset
of astrocytomas that undergo malignant progression to secondary GBM.
Studies assessing the presence of TP53 mutations as predictor of clinical outcome in diffuse
astrocytomas have been made and the results are controversial. However most of them
associated the presence of TP53 mutations to a poor prognosis [51, 54, 55]. Peraud et al. [54]
analyzed retrospectively timing, frequency, and prognostic impact of TP53 mutations and p53
protein accumulation in 159 patients consecutively treated at a single neurosurgical clinic.
TP53 mutations were frequently found and univariate analysis found that gemistocytic
subtype and TP53 mutation were associated with worse prognosis, with only the gemistocytic
subtype remaining an unfavourable prognostic factor on multivariate analysis. In non-
gemistocytic astrocytomas, a mutation in TP53 hot spot codon 175 indicated a worse prognosis
in terms of time to progression and malignancy.
Xanthoastrocytoma pleomorphic (PXAs) are rare astrocytic malignancies classified as grade II
lesions by the WHO. Because of the relative rarity of this lesion, the molecular background is
still unclear. Among the abnormalities frequently observed in astrocytic tumors, PXA shares
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only TP53 mutations, and, although TP53 mutations in anaplastic PXA have previously been
reported, the significance of this alteration for tumor malignant progression is not clear [56,
57].The high frequency of TP53 mutations in low-grade astrocytomas raises the question of
whether these alterations play an important role in the tumorigenesis of PXA. Paulus and
coworkers [58] reported the highest frequency of TP53 mutations, around 25%. However, in
contrast, Giannini et al. [59] identified mutation in only 1 of 47 samples, all of which were
nonrecurrent lesions and all lacked anaplastic transformation, while Bettegowda et al. [60]
sequenced the exomes of 12 PXAs and identified mutation in only 2 cases.
Anaplastic astrocytomas, from a clinical, morphologic and genetic point of view, represents
an intermediate stage on the route of progression to GBM. They exhibit high TP53 mutation
rate (40-70%) similar to diffuse astrocytomas and high frequency of LOH at 17p [61, 62]. In a
study of almost 200 astrocytomas of grades II-IV, 72% of anaplastic astrocytomas were found
to have a disruption in the p53 pathway [63].
An important clue to pathways involved in gliomagenesis may lie in the two GBM subtypes
that have been clinically identified [50]. Primary GBM is typically present in older patients as
aggressive, highly invasive tumor, usually without any evidence of prior clinical disease.
Secondary GBM have a very different clinical history, being usually observed in younger
patients who initially presented low-grade astrocytoma that transformed in GBM within 5–10
years of the initial diagnosis, regardless of prior therapy. The cataloging of genetic lesions in
these GBM subtypes has identified differences in their genetic profiles, predominantly in the
penetrance of specific genetic mutations. As a result, it has been proposed that primary and
secondary GBMs represent two distinct clinical entities, each developing along distinct genetic
pathways [50].
TP53 mutations are a genetic hallmark of secondary GBM, because these tumors have a high
incidence of mutations in this gene (>65%), suggesting that p53 pathway plays a crucial role
in their development tumors [62, 64-66]. TP53 mutations are the first detectable genetic
alteration in > 60% of precursor low-grade diffuse astrocytomas or in anaplastic astrocytomas
in a similar frequency, and secondary GMBs derived thereof [64, 67]. TP53 mutations also is
present in primary GMBs, but with significantly lesser frequency (25-30% of cases) [47, 67].
Giant cell glioblastoma, a histological variant of GBM, carry TP53 mutations in high frequency
(75 – 90%) [68, 69], while gliosarcoma, another GBM variant characterized by a biphasic tissue
pattern, has a lower TP53 mutation rate (23–24%) [70, 71], and identical TP53 mutations in both
gliomatous and sarcomatous components [70].
In secondary GBMs, 57% of mutations have been reported to be located in the two hotspot
codons 248 and 273; however, in primary GBMs, mutations were more equally distributed
through all exons, with only 17% occurring in codons 248 and 273 [67]. Furthermore, G:C >
A:T transitions at CpG sites were significantly more frequent in secondary than in primary
GBMs [67]. The less specific pattern of TP53 mutations in primary GBMs suggests a different
molecular mechanism underlying the acquisition of TP53 mutations in these subtypes.
Amplification of MDM2 is present in < 10% of GBMs, and this event appears to be associated
to primary GBMs with no TP53 mutations [72]. Loss of p14 ARF expression has been observed
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frequently in GBMs (76%), and correlated with homozygous deletion or promoter methylation
of the p14 ARF gene [53]. Comparing the overall frequency of p14 ARF alterations between
primary and secondary GBMs, no significant difference was observed, while p14 ARF promoter
methylation was more frequent in secondary than primary GBMs [53]. The analysis of multiple
biopsies from the same patients revealed p14 ARF methylation already in one-third of low-grade
astrocytomas [53].
But, have all these data any prognostic value for GBMs? Although there is some discordance
among different studies, promising data have already been gained. Hence, some studies
showed no association between TP53 status and outcome of GBM patients [73, 74] or between
p53 score analyzed by IHC and patient survival [75]. Schmidt et al. [76] analyzed 97 GBM cases
and found that the presence of TP53 mutations was a favorable prognostic factor. In the same
way, Ohgaki et al. [67] showed that the presence of TP53 mutations was a favorable prognostic
factor, and at the population level, univariate analysis revealed that the presence of these
mutations was predictive of longer survival; however, age-adjusted multivariate analysis
revealed no difference in survival between patients with and without TP53 alterations.
El Hallani et al. [77] showed that the Pro/Pro genotype (a functional single nucleotide poly‐
morphism at codon 72 of TP53 gene results in the presence of either proline (Pro) or arginine
(Arg) in the amino acid sequence) is significantly over-represented in young patients with
GBM (<45 years) (7 of 43 cases, 16.3%) compared to older patients (>45 years) (14 of 217, 6.5%)
(P=0.05), whereas no difference of frequencies for Arg/Arg versus Arg/Pro between the two
groups were observed. These data suggest a recessive effect of the Pro allele on the oncogenesis
of GBM in young patients. This result is in line with previous reports showing consistent
associations between the codon 72 polymorphism with age of onset in oral cancer, head and
neck carcinomas, hereditary nonpolyposis colorectal cancer, and prostate cancer [78, 79]. The
polymorphism described by El Hallani et al. [77] at TP53 codon 72 is associated with age at
onset of glioblastoma. In a study in 2009, Zawlik et al. (66) revealed that TP53 codon 72 Pro
allele was significantly associated with shorter survival among patients with GBMs carrying
a TP53 mutation (Arg/Pro or Pro/Pro), and among those treated with surgery plus radiother‐
apy (Arg/Pro).
Considering the association between mutations and treatments, recent studies have shown
that the status of the TP53 gene interferes with the effectiveness of treatment by DNA alkylating
agent temozolomide (TMZ), the most effective chemotherapeutic for GBM. Blough et al. [80]
related that GBM cell lines that did not express a functional p53 were significantly more
sensitive to TMZ than cell lines with functionally intact wild-type p53 expression, while altered
p53 expression or function had only minor effects on TMZ sensitivity in brain tumor initiating
cells and tended to decrease sensitivity to TMZ.
2.1.2. Oligodendroglial and oligoastrocytic tumors
In contrast to diffuse astrocytomas, loss of 17p and TP53 mutations are rare in oligodendroglial
tumors (~10%) and mutually exclusive to 1p/19q deletion, a hallmark alteration in oligoden‐
drogliomas (~ 70%), while oligoastrocytomas frequently carry either TP53 mutations (~40%)
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or loss of 1p/19q (~45%), indicating that oligoastrocytomas are genetically monoclonal, and
carry genetic alterations similar to either diffuse astrocytomas or oligodendrogliomas.
Furthermore, G:C > A:T transitions at CpG sites are the most frequent TP53 mutations in these
tumors [81-83]. According to Muller et al. [84] oligoastrocytomas in the temporal lobe showed
LOH on 1p and 19q less frequently (33%) than TP53 mutations (45%). In contrast, oligoastro‐
cytomas arising outside the temporal lobe demonstrated LOH on 1p and 19q in nearly 75% of
the cases while TP53 mutations were found in less than 20% [85].
Watanabe et al. [86] reported that genetic alterations in the p53 pathway are more frequent in
anaplastic oligodendroglioma (50%) than in oligodendroglioma WHO grade II (21%), and
showed that simultaneous disruption of the RB1/CDK4/p16 INK4a /p15 INK4b and the TP53/p14
ARF /MDM2 pathways occurs in 45% (9/20) of anaplastic oligodendrogliomas, suggesting that
these phenomena contribute to their malignant phenotype. Anaplastic oligoastrocytoma
typically exhibits the type and distribution of molecular lesions observed in oligoastrocytoma:
loss of 1p/19q or TP53 mutations [84].
A number of genetic alterations have been correlated with poorer response to chemotherapy
or worse overall survival in anaplastic oligodendrogliomas. Ino et al. [87] suggested that a
variety of relatively infrequent genetic alterations (EGFR gene amplification, 10q loss, CDKN2A
homozygous deletion, PTEN mutation, and TP53 mutation) were associated with worse
prognosis. Interestingly, TP53 mutation was associated with an improved likelihood of
chemotherapeutic response but with a poor overall prognosis, since responses were not
durable in the setting of TP53 mutation.
Kim et al. [83] evaluated 413 tumors confirmed as low-grade diffuse gliomas WHO grade II
(206 diffuse astrocytomas, 73 oligoastrocytomas, and 134 oligodendrogliomas) and observed
that the median survival of patients with TP53 mutation combined with IDH1/2 mutation was
significantly shorter than the observed in patients with 1p/19q loss combined with IDH1/2
mutation (51.8 months vs. 58.7 months, respectively; P=0.0037). A Multivariate analysis with
adjustment for age and treatment confirmed these results (P=0.0087) and also revealed that
TP53 mutation is a significant prognostic marker for shorter survival (P=0.0005) and 1p/19q
loss for longer survival (P=0.0002).
2.1.3. Ependymal tumors
TP53 mutations were rarely reported in ependymal tumors by molecular analysis [88, 89].
However, p53 protein is identified in about 60% of ependymal tumors [90]. Shuangshoti et
al. [91] suggested that the discrepancy may be due to expression of wild type p53 gene in tumor
cells, alternative mechanisms of p53 gene inactivation or simply a cross-reaction of the antigen-
antibody complex.
A number of studies have documented a correlation between p53 expression and tumor grade
in ependymomas [90, 92, 93]. Sharma et al. [94] analyzed p53 protein expression in 119
ependymomas tumors (17 cases were of grade I, 54 of grade II and 48 of grade III) and observed
its expression in only two cases of grade I tumors (11.5% and 6.4%). Five cases of grade II
tumors showed p53 protein expression and this percentage of nuclear positivity was very low
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(< 1.0%), while eighteen of 48 grade III tumors (37.5%) showed expression of p53 and mean
positivity was 5.5%. Manasa et al. [95] reported 66% p53 positivity, performing p53 immuno‐
histochemical analysis in 54 samples of different grades and subtypes of ependymomas and
observed that p53 indices were higher in grade II and grade III tumors (26.27 % and 26.08%
respectively) as compared to subependymomas (grade I) (7.25%). However, p53 index of
myxopapillary ependymoma (grade I) (26%) was similar to grade II and grade III tumors. But
these values did not show statistical significance (P=0.2). Papillary ependymoma (grade II)
showed p53 expression in 24% cells.
Some authors have advocated that p53 immunolabeling are important prognostic markers in
ependymomas. Zamecnik et al. [96] found that p53 immunopositivity is the strongest indicator
of aggressive tumor behavior and poor prognosis. Gaspar et al., [88] studied the p53 pathway
in primary intracranial childhood ependymomas and p53-mediated response to DNA-damage
in two newly described ependymoma xenograft models. Their findings do not suggest a role
of p53 genetic/epigenetic alterations in the tumorigenesis or progression of childhood epen‐
dymomas; however, radioresistance of these tumors might be due to alterations in p53-
mediated growth arrest. Despite the lack of TP53 mutations, immunocytochemical
accumulation of p53 occurs, particularly in tumors with poor outcome. Moreover, the data
concerning immunoexpression of the p53 protein indicate its usefulness in identification of
more aggressive clones in ependymomas and its superior predictive value [94].
2.2. Embryonal tumors
2.2.1. Medulloblastoma
The genetic and genomic understanding of medulloblastoma (MB) has evolved dramatically
in the past few years, but the role of p53 in MB pathogenesis has only initiated to be elucidated.
Patients with LFS, caused by a germline mutation in p53, develop MB at a higher incidence
than the general population [97, 98]. Similarly, p53 deficiency in mice in combination with
mutations in other genes, including poly (ADP-ribose) polymerase (PARP), the cell cycle
regulatory protein retinoblastoma (Rb), or the Sonic hedgehog (Shh) receptor Patched1 (Ptch1),
greatly increases tumor incidence [99, 100], indicating that loss of p53 can promote MB
tumorigenesis. However, in contrast with the high incidence of p53 mutations in most human
tumors, the TP53 gene is altered in <10% of sporadic human MB. Chromosome 17p, where
TP53 is located, is lost in 40% to 50% of sporadic MB tumors. However, it has been found that
losses of 17p and p53 status are unrelated in MB [101, 102].
New support for a role for p53 in MB tumorigenesis came from a better understanding of
heterogeneity underlying MB tumors. Recently, several groups were able to demonstrate that
although morphologically similar, MBs could be divided into several subgroups on the basis
of expression profiling [103, 104]. A consensus meeting resulted in the current molecular
subclassification of MB into four subgroups: wingless (WNT), sonic hedgehog (SHH), group
3, and group 4 [105]. Hopefully, in the near future, this subclassification will be used to select
targeted therapies and improve understanding of the behavior of this disease.
Alterations in TP53 gene – Implications in Tumorigenesis Process and Prognosis in Central Nervous System Cancer
http://dx.doi.org/10.5772/58334
137
As observed for other CNS, reports detailing the prognostic impact of TP53 mutations in MB
offer conflicting conclusions. Pfaff et al. [106] reported that TP53 mutations occur at low
frequency in MBs but are overrepresented in the prognostically favorable subgroup featuring
alterations in the Wnt pathway. In addition, because no correlation between TP53 mutation
status and patient outcome was observed in more than 300 patients, these authors concluded
that TP53 mutation is not a universal prognostic marker for MB. These results were supported
by Lindsey et al. [107] in an independent and representative series of all major established
clinical and molecular subtypes of MBs. Nevertheless, Gessi et al. [108] reported that TP53
expression is associated with rapid disease progression and poor prognosis in patients with
metastatic MB, with a statistically significant inverse correlation between TP53 expression and
patient survival.
A large whole-genome and exome sequencing efforts recently published by different groups
revealed an additional, albeit small number, of TP53 mutations in MB [109, 110]. These
independent groups found TP53 mutations enriched in the SHH group and associated with
poor survival. Zhukova et al. [111] evaluated the association of TP53 mutations, molecular
groups, and survival in MBs patients and confirmed that TP53 mutations are enriched among
SHH MBs, in which they portend poor outcome and account for a large proportion of treatment
failures in these patients.
Carvalho et al. [112] were the first to investigate the role of the TP53 Arg72Pro SNP as a potential
risk factor and/or prognostic marker of MB by performing a case–control analysis using a
polymerase chain reaction-restriction fragment length polymorphism approach. The date
suggested that, although there is no association between the TP53 Arg72Pro SNP and MB risk,
the Pro/Pro genotype is associated with shorter overall survival of patients submitted to
adjuvant therapy.
Some researchers justify the p53 inactivation in MB tumors lacking TP53 gene mutations
through alternative mechanisms. Mendrysa et al. [113] supported MDM2 as an important
contributor to the inhibition of p53 in SHH-driven MB tumorigenesis. In cerebellar develop‐
ment, MDM2 is required to inhibit p53-mediated apoptosis in granular neuronal precursors,
the presumed cell of origin for MB tumors of the Shh subgroup, and MDM2 deficiency potently
restricts cerebellar tumorigenesis in Ptch1+/− mice, a model of human Shh-induced MB.
2.2.2. CNS primitive neuroectodermal tumors
The presence of TP53 mutations have been identified in CNS primitive neuroectodermal
tumors (PNETs), mainly in adult patients [114]. However, TP53 mutations in PNET have also
been occasionally reported in children [115, 116], but the overall incidence of somatic TP53
mutation in pediatric CNS-PNET seems to be very low [115]. Gessi et al. [117] analyzed the
clinicopathologic and molecular features of 12 cases of PNETs in adult patients. The p53
staining showed strong nuclear positivity (>20% of stained nuclei) in 9 cases, evidencing the
presence of TP53 mutations in these tumors. The use of single strand conformation polymor‐
phism (SSCP) followed by sequencing of the TP53 gene showed point mutations of this gene
in 4 of these 9 cases, identifying 5 mutations in exons 4, 5, 7, and 8.
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Although the presence of TP53 mutations seems to mainly occur in adult s-PNETs, nuclear
accumulation of p53 has been described to be frequent not only in adults but also in pediatric
CNS-PNETs [118]. This observation led to the hypothesis that the p53 pathway is pivotal in
CNS-PNET biology and can also be activated by mechanisms other than mutation.
Immunohistochemical staining for the p53 gene product is a good predictor of poor outcome
in PNETs. Robert et al. [119] observed stained intensely for the p53 protein in 10 patients (n=40)
with PNETs and 11 had weakly staining nuclei, while 19 specimens had no staining. The
patients with specimens that stained intensely had a statistically significant decreased disease
free survival (P=0. 03). Intense p53 immunostaining may predict a poor prognosis in PNETs
of childhood [120], however, the significance of p53 in recurrent CNS PNETs is unknown.
2.2.3. Atypical teratoid/ Rhabdoid tumor
The role of p53 in atypical teratoid/ rhabdoid tumor (AT/RT) is also poorly understood. Cell
lines established from malignant rhabdoid tumor (MRT) show overexpression of p53, without
associated TP53 gene mutations [120]. On the other hand, missense mutations in TP53 were
reported in 3/6 cases of non-CNS MRT [121]. Knockdown of SMARCB1 in cell lines and animal
models results in activation of p53 [122, 123]. Intriguingly, combined inactivation of Smarcb1
and TP53, but not Rb or p16ink4a, leads to accelerated development of MRT in mouse models
[122, 124]. These data have led to the hypothesis that two successive hits involving SMARCB1
and TP53 may contribute to malignant transformation and tumor development. Venneti et
al. [125] studied the expression of p53 and determined TP53 mutational status in 36 AT/RT and
16 non-CNS MRT patients. They also studied the relationship of p53 expression with its
regulators p14ARF/MDM2 in AT/RT and non-CNS MRT. p14 ARF expression was seen in many
cases, which correlated positively with p53 and inversely with Mdm2 immunostaining in AT/
RT, while TP53 mutational analysis in 19/25 AT/RT and 8 in 11 non-CNS MRT cases showed
point mutations in only 3 AT/RT cases, suggesting that p53 expression was driven mainly by
p14 ARF.
2.3. Choroid plexus tumors
Choroid plexus tumors (CPT) are rare tumors, often occurring during childhood. Previous
studies have shown high frequencies of germline TP53 mutations in patients with CPT (44–
100%) irrespective of family history [126, 127]. According to the latest clinical criteria for LFS,
it is suggested that patients with CPT should be considered for TP53 testing [128, 129]. In
addition, somatic mutations of the TP53 gene and subsequent accumulation of p53 protein
have been described in up to 50 % of choroid plexus carcinomas (CPC) [130, 131].
The prognostic role of p53 in choroid plexus carcinomas has been recently demonstrated.
Tabori et al. [131] studied 54 patients with CPTs, including CPC (n=36) and choroid plexus
papilloma (CPP) (n=18), and demonstrated that patients with CPC who have low tumor total
structural variation and absence of TP53 dysfunction had a favorable prognosis and could be
successfully treated without radiation therapy. Krzyzankova et al., [132], investigated the role
of p53 in the growth-inhibitory potential of a variety of anticancer agents in the immortalized
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rodent choroid plexus epithelial cell line Z310 and observed that growth-inhibitory activity of
vincristine, doxorubicin, carboplatin, etoposide, and TMZ was significantly impaired by
silencing of TP53, showing the potential predictive role of p53 in choroid plexus carcinomas.
2.4. Meningiomas
Few studies have examined the TP53 gene directly for mutations in meningiomas, [133-135],
and these studies typically have not observed mutations in this gene, although rare mutants
have been described, mainly associated with malignant histology [134, 136]. One group
working on specimens from Korean patients has documented a rate of nearly 40% of p53 over-
expressing meningiomas as having mutations, and observed that the mutation rate was
associated with both histological grade and recurrence [137].
In contrast the low frequency of TP53 point mutations, expression of p53 was found in 10% to
90% of meningiomas [138], but their role in pathogenesis is still uncertain. Studies suggested
the involvement of the p53 pathway in meningioma development: the correlation of p53
protein expression with histological tumor grade and meningioma recurrence [139]; methyl‐
ation of the p14 ARF gene in 8.6% of benign, 20% of atypical and in 50% of anaplastic meningi‐
omas and loss of detectable Mdm2 protein in high grade meningiomas [140]; defective p53
response to gamma ray stress in meningioma cells [141]. In addition, the NF2 protein product
was reported to increase p53 stability through downregulation of Mdm2 levels in mouse
fibroblast [142]. It follows that loss of NF2 may increase the likelihood of p53 suppression, thus
decreasing tumor suppression activity and providing a possible mechanism for the involve‐
ment of the p53 pathway in meningiomas.
Many studies have examined benign and atypical/malignant meningiomas for over-expres‐
sion of the p53 protein with diverse results: p53 over-expression has been reported in 0–10%
of benign, 50–72.7% of atypical and 77–88.9% of anaplastic or malignant meningiomas [143].
Despite the differing rates, all of the studies are consistent, with atypical/malignant tumors
showing higher rates of over-expression than benign meningiomas. However, studies on the
biological significance of p53 over-expression are highly contradictory. While over-expression
of p53 has been associated with recurrence in some studies [139, 144], no association has been
found in others [133, 145]; and still other studies have suggested that expression of high levels
of p53 may be protective against recurrence [146].
Terzi et al. [147] analyzed the immunohistochemical expression of Ki-67, p53, p21, p16, and
PTEN proteins in 130 meningiomas (64 benign, 39 atypical, and 27 malignant meningiomas)
using tissue microarray and demonstrated that Histological grade, p53, Ki-67 labeling indices,
and overexpression of p16 were strongly associated with decreased event-free survival in
univariate analysis and Ki-67 and p53 labeling indices are useful additional tools in discrimi‐
nating atypical from benign or anaplastic meningiomas.
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3. Epigenetic mechanisms in CNS tumors
Epigenetics is defined as mitotically heritable changes in gene expression that are not due to
changes in the primary DNA sequence. The coordinated interaction of these changes regulates
gene expression activity and several types of epigenetic marks work in concert to drive
appropriate gene expression, like DNA methylation at CpG dinucleotides, covalent
modifications of histone proteins, non-coding RNAs, and other complementary mechanisms
controlling higher order chromatin organization within the cell nucleus. Epigenetic alterations
have been recognized as important mechanisms in neoplastic transformation, malignant
progression of cancer, and although epigenetic changes are somatically inheritable, they are
reversible and hence may represent actionable targets for novel therapies [148, 149]
Epigenetic changes are often observed at the earliest stages of neoplasia within the altered
tissue stem and progenitor cells. These observations have led to the epigenetic progenitor
model [149]. This model explains that transformation to a malignant state occurs in three steps.
First, there is an expansion of an epigenetically permissive population due to an essential early
epigenetic disruption of stem/progenitor cells. Second, an initiating genetic alteration in an
oncogene or tumor suppressor gene occurs. Finally, genetic and epigenetic plasticity resulting
in an enhanced ability to stably evolve the phenotype is observed. An important difference to
the clonal genetic model is that the epigenetic ‘hits’ occur early, and are necessary to create an
appropriate expansion of a polyclonal population, that is the cellular substrate for subsequent
genetic alterations and transformation [150].
To better understand the multiple cellular pathways involved in their development, estab‐
lishment markers of resistance to traditional therapies, and contribution to the development
of targeted therapies, a comprehensive appreciation of the integrated genomics and epige‐
nomics of CNS tumors is needed [151].
3.1. DNA methylation of gene TP53
Hypermethylation of promoters usually occurs at CpG islands. Methylation of TP53 was
reported as a mechanism for its inactivation in neoplasias, such as acute lymphoblastic
leukemia, multiple myeloma, malignant glioma cells, and brain metastases of solid tumors
[152]. Since the promoter region of TP53 does not contain a classic CpG island, methylation of
one or two sites may produce a proportionately greater effect in downregulation of transcrip‐
tion compared to a tumor suppressor gene with a classic CpG island in the promoter [153].
The TP53 promoter region has been sequenced and basal promoter activity localized to an 85
bp region (nucleotide 760–844) that is indispensable for full promoter activity and the TP53
promoter has putative binding sites for transcriptional factors [154]. Schroeder and Mass [155]
have shown that methylation in the promoter region of the p53 gene reduces reporter gene
activity. They found down-regulation of p53 in cultured cells transfected with a plasmid
incorporating a TP53 promoter containing methylated CpG dinucleotides. Furthermore, this
region has been shown to be methylated in several cancers [156].
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Analyses of methylation of TP53 promoter region are controversial. While some researchers
reported low frequencies of TP53 methylation in neuroblastic tumors (0/44), astrocytomas
(2/24, 8%), GBM (1/43, 2%) [157], oligodendroglial tumors (0/41) and ependymomas (0/7) [158],
other authors observed a higher frequency [159, 160]. The reason for this discrepancy remains
to be clarified.
Amatya et al. [159] assessed whether promoter methylation was present in cells of six malignant
gliomas and whether there is an association with reduced expression of TP53 mRNA and
protein. They also assessed the frequencies of disruption of the p53/p14 ARF pathway in 49 low-
grade astrocytomas (40 fibrillary astrocytomas and 9 gemistocytic astrocytomas), 42 oligoden‐
drogliomas and 18 oligoastrocytomas. The Methylation-specific PCR (MS-PCR) revealed
methylation of the promoter region of the TP53 gene in three (U87MG, LNT-229, T98G) out of
six malignant glioma cell lines. Real time RT-PCR revealed that two malignant glioma cell lines
(U87MG and T98G) led to up-regulated expression of TP53 mRNA and protein after treatment
with 5-aza-2’-deoxycytidine (5-aza-dC, an epigenetic modifier that results in DNA demethy‐
lation), suggesting that promoter methylation is associated with reduced expression in some
malignant glioma cells. TP53 promoter methylation in primary tissue of low-grade gliomas
was observed in 29/48 (60%) low-grade astrocytomas, 11/18 (61%) oligoastrocytomas, and
31/42 (74%) oligodendrogliomas, while promoter methylation of the p14 ARF was detected by
MS-PCR in 5/49 (10%) low-grade astrocytomas, 7/18 (39%) oligoastrocytomas, and 15/41 (37%)
oligodendrogliomas. Briefly, alterations of at least one of TP53 promoter methylation, p14 ARF
promoter methylation, and TP53 mutations were found in 43/49 (88%) of low-grade astrocy‐
tomas, 15/18 (83%) of oligoastrocytomas, and 35/42 (83%) oligodendrogliomas, suggesting that
disruption of the p53/p14 ARF pathway is frequent in all histological types of low-grade glioma.
Almeida et al. [160] evaluated the promoter hypermethylation profile of the TP53 gene in 90
extra-axial brain tumors (48 meningiomas, 23 schwannomas and 19 metastases) using MS-PCR
and sequencing. The group showed that the methylation of the TP53 gene is an important
event associated with extra-axial brain tumors, since 37.5% of meningiomas, 30% of schwan‐
nomas and 52.6% of metastases were hypermethylated. When tumor grade was compared,
35.3% of benign tumors and 48% of malignant tumors were methylated, and these results
suggested that TP53 methylation can be involved in the progression of these tumors.
3.2. The new insights of MicroRNAs/TP53 in cancer
MicroRNAs (miRNA) are a large class of small, non-coding RNAs, 21 – 28 nucleotides long,
produced naturally in cells after being cut into segments from larger strands of RNA by the
enzyme Dicer. They function by binding to complementary sites on the 3’-untranslated region
(3’-UTR) of genes and promoting the recruitment of protein complexes responsible for
impairing translation and/or decreasing the stability of mRNA [161, 162]. A specific miRNA
may simultaneously regulate multiple targets, thereby enabling complex changes in protein
expression profiles. Furthermore, a single target can be regulated by multiple miRNAs, and
upstream regulation of a given miRNA can involve multiple regulators at different steps of
miRNA biogenesis. Thus, miRNAs take part in complex regulatory networks that may
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influence almost every cellular process [163]. Currently, 1, 048 human microRNAs are known
to modulate approximately 3 % of all genes and up to 30 % of protein-coding genes. Vital for
protein expression, microRNAs are integrally associated with both normal and abnormal
biological processes [164].
miRNAs play important roles in the regulation of normal gene expression at developmental
timing, cell proliferation and apoptosis [165]. As these processes are altered in cancer cells,
there are in literature several studies that were undertaken to provide evidence for an
involvement of miRNAs in cancer formation. miRNA-encoding genes as well as mRNA-
encoding genes have been meanwhile classified as oncogenic or tumor suppressive genes
according to their function in cellular transformation and expression in tumors [166, 167].
Furthermore, tumor cells seem to undergo a general loss of miRNA expression, and forced
reduction of global miRNA expression promotes transformation [168]. Interestingly, miRNAs
cluster within fragiles sites and other genomic regions frequently altered in cancers [169].
Because of their role in tumor formation, miRNAs may be very useful for the classification,
diagnosis, prognosis, and therapy of malignancies [166, 167].
Profiling miRNA provides an attractive, novel, and non-invasive biomarker for tumor
diagnosis and prognosis. Molecular biology techniques, such as Northern blot, RNase
protection assay, and primer extension assay can measure expression of a miRNA. The small
size of miRNAs initially hampered polymerase chain reaction-based methods. However, PCR-
based techniques have become very popular since the development of adaptor-mediated
quantitative real-time PCR (qRT-PCR) due to their high sensitivity [170]. Microarray techni‐
ques are widely used to comprehensively assay the entire miRNome (the global miRNA
expression profile) in tissues or in cell lines [171]. In addition to microarray and qRT-PCR,
miRNomes are obtained by in situ hybridization [172] and serial analysis of gene expression
adapted for small RNAs [173]. Overall, these technical improvements are expected to greatly
widen the repertoire of miRNAs in a variety of biological systems.
p53 is a transcription factor, so transactivates or represses many protein-encoding genes and
this underlies much of its tumor suppressor function. Recently, it has been reported that p53
directly transactivates specifics miRNAs [174]. miRNA have also been shown to target p53
and/or components of p53 regulatory pathways affecting its activities directly and/or indirectly
[175, 176].
Several reports shed light on the involvement of miRNAs in the p53 pathway. He et al. [177]
profiled miRNA gene expression in wild-type (wt) and p53-deficient cells and found that the
miR34s (miR-34 gene family, including miR-34a, b and c) was among the most upregulated in
wt p53 cells. In addition, Luan et al. [178] analyzed the expression levels of miR-34a in human
glioma cell lines (U251, A172 and SHG-44) using real time quantitative PCR and compared
with that observed in normal brain and determined its role in cell proliferation, cycle distri‐
bution, apoptosis and capabilities of in vitro migration and invasion of p53-mutant glioma
cells. The results showed that miR-34a is remarkably reduced in p53-mutant glioma cell line
U251, that had a mutation of codon 273 (CGT/CAT; Arg/His) in exon 8 than other p53-wild
glioma cell lines A172, SHG-44 and normal brains.
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miR34s are induced after genotoxic stress in a p53-dependent manner in vitro and in vivo.
miR-34b and-34c are clustered at chromosome 11, whereas miR-34a is located in a separate
genomic locus. p53 directly activates both pri-miRNAs. The miR-34s seem to be critical
downstream effectors of p53, as ectopic expression of the miR-34s recapitulate the phenotype
of p53 activation. The miR-34s promotes repression of several direct targets, such as Bcl-2,
Cdk4, hepatocyte growth factor receptor (MET), and other, resulting in cell cycle arrest,
apoptosis, and senescence [179] (Figure 3). Several other laboratories corroborated the finding
that miR-34s are critical components of the p53 network [180-182]. Taken together, these results
support a pivotal downstream role of miRNAs in the regulation of the p53 pathway.
Figure 3. Representation of p53 and the miR-34 family interactions. The p53 protein stimulates the transcription of
miR34s, which inhibits oncoproteins and leads to cell senescence, apoptosis and cell cycle arrest.
As cell cycle arrest, senescence, and apoptosis are tumor suppressive mechanisms, the
inactivation of members of the miR-34 family, which induce these cellular responses, may be
a selective advantage for cancer cells. Besides decreased expression of MiR-34 due to inacti‐
vating mutations of p53, the miR-34 encoding genes themselves may be targets for mutational
or epigenetic inactivation in cancer. For example, loss of miR34a expression was observed in
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neuroblastoma, which may be due to the relatively common deletion of a region on chromo‐
some 1p36, which encompasses miR-34a [183]. However, the mechanisms leading to decreased
expression of miR-34s require further exploration.
Other miRNAs may be important in the p53 network. miR-30c, -103, -26a, -107, and-182 were
induced clearly, although less robustly, upon DNA damage in a p53-dependent manner [181].
In another approach, the searching for p53-binding elements in DNA sequences near miRNAs
identified miR-129 as a good candidate for regulation by p53 [184]. miR-125b, a brain-enriched
microRNA, was identified as a bona fide negative regulator of p53 in both zebrafish and humans
[185]. Recently, Hu et al. [186] showed that miR-504 directly represses p53 expression and
function in human cell lines.
Since recent studies have indicated that p53 enters into miRNA world [187], some researchers
provided important insights into the central roles of miRNAs in a well-known tumor sup‐
pressor network, the p53 pathway, which may provide a route to therapeutic miRNA inter‐
vention in CNS tumors. Shyamal et al. [188] were the first to demonstrate that miR-34a directly
targets the MAGE-A family of oncogenes, disengaging p53 from MAGE-A–mediated repres‐
sion. The group demonstrated that miR-34a directly targets the 3 ′ UTR of MAGE-A genes and
decreases MAGE-A protein levels in medulloblastoma cell lines. This decreasing in MAGE-
A results in a concomitant increasing in p53 and its associated transcriptional targets, p21/
WAF1/CIP1 and, importantly, miR-34a. This establishes a positive feedback loop where
miR-34a is not only induced by p53 but increases p53 mRNA and protein levels through the
modulation of MAGE-A genes and a consequence of this mechanism is that sensitizes medul‐
loblastoma cells to chemotherapeutic agents via delayed G2/M progression and increased
apoptosis.
Recently, Suh et al. [189] identified two miRNAs (miR-25 and-32) as p53-repressed miRNAs in
glioblastoma multiforme cells through p53-dependent negative regulation of their transcrip‐
tional regulators, E2F1 and MYC. The study provided compelling evidence that expression of
these miRNAs causes tumor suppression through mechanisms that lead to accumulation of
p53 protein, by directly targeting Mdm2 and TSC1, leading to inhibition of cellular prolifera‐
tion through cell cycle arrest. Thus, there is a recurrent autoregulatory circuit involving
expression of p53, E2F1, and MYC to regulate the expression of miR-25 and-32, which are
miRNAs that, in turn, control p53 accumulation. Significantly, overexpression of transfected
miR-25 and-32 in cells of GBM inhibited growth of these cells in mouse brain in vivo. The results
define miR-25 and-32 as positive regulators of p53, underscoring their role in tumorigenesis
in glioblastoma.
4. The cancer stem cell model
Until a few years ago, the brain was thought to lack a stem cell population, but actually, it is
now known that there are two regions of the adult human brain that contain neural stem cells
(NSCs) (a group of self-renewing cells in the nervous system that can generate both neurons
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and glia): the dentate gyrus of the hippocampus and the subventricular zone. NSCs can form
neurons, astrocytes and oligodendrocytes in vitro, although their normal physiological role in
the adult human brain is disputed [190].
With the accumulation of knowledge concerning the stem cell and the mechanisms regulating
their behaviour, it was noted that many of the characteristics of stem cells were also present
in cancer. These findings reinforce the “cancer stem cell model”, which states that the cellular
heterogeneity within the tumor is ascribed entirely to the differentiating tumor cells that derive
from the cancer stem cells (CSCs), that can be defined as cells that possesses the capacity to
self-renew and to originate the heterogeneous lineages of cancer cells that comprise the tumor.
The term ‘‘tumor-initiating cell’’ also has been used to describe a cell with the potential to
initiate a tumor. This term are essentially functionally equivalent to CSCs if it is used to refer
to the subclones of cells within an established tumor that gives rise to a new tumor when
transplanted [190-192].
CSCs were first observed by John Dick’s group in acute myeloid leukemia and posteriorly
other researchers reported CSCs in solid tumors, including those formed by breast, colon,
prostate, pancreatic, lung, liver and brain [193-196], Subsequently there has been a large
amount of work to identify the cancer stem cell population, and to study its role in progression
of disease and resistance to treatment, allowing many experimental therapies targeting cancer
stem cells can be developed and tested in preclinical models [190, 195, 196].
CSCs have been isolated from a wide range of CNS neoplasms, including adult and pediatric,
anaplastic oligodendrogliomas and malignant medulloblastomas [197]. For gliomas, several
researchers isolated brain tumor stem cells (BTSC) from primary tumors based in the ability
to form neurospheres NSCs do and other criteria: ability to be serially transplanted; unique
ability to engraft; ability to recapitulate the tumor of origin morphologically and immuno‐
phenotypically in xenografts [198].
4.1. P53 role in neuronal and brain tumor stem cell
In the ependymal cell lining of the lateral ventricle wall as well as most cells of the subven‐
tricular zone, including astrocytes and progenitors, abundance of nuclear p53 is evident and
in agreement with the down-regulation of p53 in differentiating cells observed during
embryogenesis. The nuclear p53 immunoreactivity is absent or found at low levels in the
majority of the mature brain, including differentiating cells in the rostral migratory stream,
suggesting that p53 is preferentially expressed in neural precursors [113]. Several studies show
the important role(s) of p53 in the regulation of mammary [199], hematopoietic [200], embry‐
onic and neuronal stem cells [201] by regulating self-renewal, symmetric division, quiescence,
survival, and proliferation.
Meletis et al. [202] demonstrated that TP53 is expressed in the neural stem cell lineage in the
adult brain and negatively regulates proliferation and survival, and thereby self-renewal, of
neural stem cells. Analyses of the neural stem cell transcriptome identified the dysregulation
of several cell cycle regulators in the absence of p53, most notably a pronounced downregu‐
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lation of p21 expression. These data reinforce the p53 role as a suppressor of tissue and cancer
stem cell self-renewal.
Armesilla-Diaz et al. [203] demonstrated that p53 controls the chromosomal stability, prolif‐
eration and differentiation patterns of embryonic mouse olfactory bulb stem cells. The group
reported that the absence of this protein increases the number of neurosphere-forming cells
and the proliferation of these stem cells, and observed that differentiation of p53 knockout-
derived neurospheres was biased toward neuronal precursors. Moreover, the relevance of p53
in maintaining chromosomal stability in response to genotoxic insult was demonstrated, and
additionally, the results showed that neurosphere stem cells are highly resistant to long-term
epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) deprivation in a p53-
independent fashion, and they preserve their differentiation potential.
While the role of p53 in apoptosis of neuronal cells was well elucidated [202, 204, 205], its
function in astrocytes, oligodendrocytes and their precursors is poorly understood. Oligoden‐
drocyte precursors cultured in vitro can undergo p53-dependent differentiation although the
cells appear to have a low basal level of p53 expression [206]. Both oligodendrocytes and
astrocytes can undergo apoptosis following infection with an adenovirus expressing p53 [207].
CSCs exhibit genetic or chromosomal alterations in addition to aberrant differentiation
properties, unlike the normal stem cells [208]. It is important to highlight the fundamental
differences between normal stem cells and CSCs. The first are known for the vigilance with
which their proliferation is controlled and for the care with which their genomic integrity is
maintained, while CSCs lack such ability [209]. The cell-of-origin of CSCs remains elusive,
however evidences indicate that CSCs may originate from malignant transformation of normal
stem cells, because of the perennial nature and high proliferative potential characteristics of
stem cells. Some studies have shown that oncogene activation or tumor suppressor gene
inactivation increased the frequency of tumor formation in primitive nestin-expressing cells
but not in the more differentiated glial fibrillary acidic protein (GFAP)-expressing astrocytes
[210, 211] while other researches indicate that differentiated astrocytes and NSCs may be
equally permissive to transformation when genomic alterations are introduced [212].
The role of p53 in BTSC has not been well established, however based on current understanding
of its function in neural precursors available in the literature, several hypotheses may be
develop. First, loss of p53 may increase the self-renewal and proliferation of neural stem and/
or lineage-restricted progenitors, thereby expanding the pool of cells available for additional
mutations in specifics oncogenes. Another hypothesis is that, depending on cellular context,
p53 can both inhibit or promote cell differentiation, as well as influence cell fate decisions, so
the differentiation program of neural precursors can be changed by p53 mutation. Lastly,
accumulated evidences support a role for p53 in the suppression of cell migration, although
much focus on p53 is directed at its growth inhibitory properties [213]. The neurogenic niche
has been shown to be important for the maintenance of stem cells in an undifferentiated state,
and the premature exit of NSCs from the neurogenic niche may alter their capacity for tissue
invasion or differentiation program in the absence of p53 [214].
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The number of studies concerning the cellular, molecular, and environmental factors that
regulate p53 function in NSCs has increased drastically and brought a better understanding
of these factors, and together with the advances in molecular biology techniques, provided
much valuable information about the role of p53 in BTSCs. This scenario stimulates future
studies exploring the significance of p53 alterations for prognosis and prediction of treatment
response that would help development of individual treatment strategies as well as help
clarifying the clinical importance of cancer stem cell biology.
5. p53-based gene therapy: GBMs as an example
Malignant tumors within the brain remain a therapeutic challenge, but current strategies tested
in animal models as well as in the clinics have shown promising results. The rapid progress
in knowledge of the p53 pathway have led to many different approaches to p53 based cancer
therapy as mentioned previously and the field has excited great interest both academically and
commercially [215]. The long awaited molecular treatment of GBM and other CNS tumors and
utilization of knowledge surrounding p53 may then be foreseeable goals in the future. It will
also be important and likely therapeutically be effective to combine gene therapy with other
therapeutic modalities, including the standards-of-care [216].
Standard treatment of care for GBM, for example, consists of surgical resection, followed
by  radiotherapy  and  chemotherapy  [217,  218].  Despite  significant  advances  in  current
treatment  approaches,  including  the  gamma knife  (radiation)  and  TMZ (chemotherapy)
[217,  219],  GBM  continues  to  present  a  poor  prognosis,  with  median  survival  still  re‐
mains less than 15 months. It is important to remember that GBMs are the most common
and least  curable among CNS tumors [220].  Moreover,  for  this  type of  tumor,  complete
resection is practically impossible due to its diffuse nature and the proximity of the tumor
to vital  brain structures.  Moreover,  it  often recurs in an area close to the original  resec‐
tion cavity [221]. The intrinsic resistance of glioblastoma cells to radiotherapy and chemo‐
therapy confers another therapeutic challenge of this disease [222].  On the other hand it
has been reported that invading GBM cells, which give rise to recurrences, are resistant to
cytotoxic therapies due to the constitutive activation of antiapoptotic signaling pathways
[221].  Novel therapeutic approaches and adjuvants to be employed in combination with
standard  therapeutic  strategies  are  sorely  needed  for  GBM  patients,  because  although
isolated traditional therapies allow an increase in the quality of life and survival of these
patients, they are not curative and long-term survival is very rare [221, 223, 224].
Gene therapy for CNS tumors is evolving every year, especially for GBM, with the ultimate
goal being specific delivery of therapeutic genes or oncolytic viruses to eliminate the tumor.
Besides results in cell death, also enhanced immune responses to tumor antigens and disrup‐
tion of the tumor microenvironment [216]. A variety of gene therapy strategies has been
examined in GBM preclinical models and clinical trials and includes the use of selective
replication-competent oncolytic viruses, non-replicating viral vectors or normal adult stem/
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progenitor cells for the delivery of immunostimulatory genes, cytotoxic genes and genes
modulating the tumor microenvironment [216].
The fact that p53 pathway is activated in tumor cells, but not in normal cells, provides a
potentially important therapeutic selectivity, indifferent of which signal in the tumor cells
activates p53 following its restoration [225]. In this context, the evidences that tumor cells, but
not normal cells, have a cellular environment that activates the p53 pathway would create a
setting of an advantageous therapeutic index, whose main objective is the development of
interventions that selectively kill tumor cells instead normal cells [225].
Different approaches to achieve this goal are already in various stages of development and a
diversity of small druglike molecules targeting the p53 system have been developed and
several are now in clinical trials. Of critical importance has been the development of: agents
which can increase active p53 in tumor cells by interfering with the p53–MDM2 interaction are
therefore considered to have therapeutic utility in sensitizing tumor cells for chemo-or
radiotherapy, such as the Nutlins [226, 227]; molecules that activate p53 via direct interaction
with p53 itself, as PRIMA-1, of which there is evidence of induction of expression of mediators
of p53-dependent apoptosis such as Puma, Noxa, and Bax in cells with mutant p53 [228, 229];
small molecules activating p53 family members in a p53 mutant or deficient background;
molecules activating p53 by inhibiting class III histone deacetylases, nuclear export, transcrip‐
tional and nucleolar distuption. These screens in combination with RNAi based approaches
are of utmost importance for the discovery of new targets for therapy in the p53 pathway [215].
Transfection of wild-type p53 in order to normalize function in mutant p53-containing tumors
has been a long-pursued goal of gene therapy. Mercer et al. [230] initially demonstrated that
plasmid-mediated transfection of the p53 gene is capable of suppressing cell growth in gliomas
by inhibition of G0/G1 progression into S phase. Kock et al. [231] and Gomez-Manzano et al.
[232] were among the first to demonstrate that delivering the p53 gene using an adenovirus
vector (Ad-p53) resulted in high levels of apoptosis in glioma cell lines, by elevation of the
levels of the p21 (cell cycle-related) and Bax (apoptosis-related) proteins. Frederick et al.[233]
undertook a phase I trial of Ad-p53 in the treatment of patients with recurrent malignant
gliomas with the purpose of determine the clinical toxicity of Ad-p53 and obtain molecular
information regarding the expression and distribution of the p53 protein after intratumoral
treatment of human gliomas with Ad-p53. Thus, their results conclude that Intratumoral
injection of Ad-p53 allowed the exogenous transfer of the p53 gene and expression of func‐
tional p53 protein, with minimaltoxicity observed.
To the generation of an effective systemic anti-tumor immune response, it is necessary the
development of strategies that promote the GBM tumor cell death, which is essential not only
to kill tumor cells and reduce tumor burden, but also to induce the release of inflammatory
molecules from dying tumor cells [234]. Drug combinations have been developed to selectively
kill cancer cells that lack p53 function while protecting normal cells. The potential to explore
the defective checkpoint status of cells with inactive TP53 genes has also been largely recog‐
nized and in part stimulated the search of drugs that can inhibit PLK1, AURKB, and other
proteins that regulate the G 2 /M checkpoint [235]. Shchors et al. [236] used a preclinical model
of GBM in combination with a switchable p53 allele to model the therapeutic effect of p53
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pathway restoration. It was observed that the therapeutic efficacy of p53 pathway restoration
was greatly influenced by both the initial mechanism of p53 pathway-inactivating mutation
and the temporal manner in which the selective pressure elicited by p53 pathway restoration
was applied. Their results suggested that intermittent dosing regimens of drugs that restore
wild-type tumor-suppressor function onto mutant, inactive p53 proteins will prove to be more
efficacious than traditional chronic dosing by similarly reducing adaptive resistance.
This topic focused on GBM because of its poor prognosis and the target for most clinical trials.
However, it is important to recognize that there are many other brain tumors which are also
targets for gene therapy. Recently, Kunkele et al. [227] observed that targeting the p53-MDM2
complex using nutlin-3 significantly reduced cell viability and induced either apoptosis or cell
cycle arrest and expression of the p53 target gene p21 in 4 of 6 human medulloblastomas cell
lines. However, UW-228 and DAOY cells harboring TP53 mutations were almost unaffected
by nutlin-3, showing that the mutational status of the gene interfere in the efficacy of the
treatment. MDM2 knockdown in medulloblastoma cells by siRNA mimicked nutlin-3 treat‐
ment, whereas expression of dominant negative p53 abrogated nutlin-3 effects. Oral nutlin-3
treatment of mice with established medulloblastoma xenografts inhibited tumor growth and
significantly increased survival. Hence, the authors suggested that inhibition of the MDM2-
p53 interaction with nutlin-3 is a promising therapeutic option for medulloblastomas with
functional p53 that should be further evaluated in clinical trials.
6. Conclusion
After a detailed review of the literature about the role of the TP53 gene in the genesis and
development of CNS tumors we can conclude that both genetic and epigenetic alterations that
inactivate this gene are directly related to these phenomena in specific histopathological
tumors. In addition, several studies have investigated the predictive value of TP53 mutation
status and have shown that specific types of genetic mutations can alter the function and
expression of p53, influencing tumor response to treatment and patient outcome, revealing
thus to be a useful prognostic tool. Genetic alterations in the p53 pathway are early events in
the molecular pathogenesis of diffuse astrocytoma and the highest frequencies of allelic loss
and/or mutation of TP53 gene are mostly seen in gliomas, and are a genetic hallmark of: low-
grade diffuse astrocytomas (> 60%), mainly in gemistocytic astrocytomas that carry TP53
mutations in up to 80% of the cases; anaplastic astrocytomas (40-70%); secondary glioblastoma
(>65%); oligoastrocytomas (~40%). Genetic TP53 mutations are rarely found or seen less
frequently in other CNS tumors, however, some studies have shown that some changes have
found important prognostic value. Recently, our group investigated the presence of numerical
aberrations of chromosome 17 and TP53 in 5 subjects with brain metastasis from breast cancer
using dual-color fluorescence in situ hybridization experiments. Deletion of TP53 was the most
frequent alteration observed, suggesting that if this alteration is present in the primary tumors,
breast tumors with loss of TP53 copies have a poorer prognosis and a higher chance for
metastasis [237].
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Epigenetic events in TP53 gene has been increasingly recognized as an alternative mechanism
for inactivation of function of a tumor suppressor gene. Although less frequently, TP53
epigenetic abnormalities has been found in CNS tumors and several reports shed light on the
involvement of mainly DNA methylation and miRNAs in the p53 pathway, suggesting that
this process can be involved in the genesis and progression of these tumors. Clearly, additional
studies can provide important insights into the central roles of miRNAs in the p53 pathway,
as well as TP53 promoter methylation, which may provide a route to therapeutic intervention
in CNS tumors.
Due the difficulty to the use of traditional therapeutic modalities such as chemotherapy and
radiotherapy in the CNS tumors, especially in high grade tumors, such as glioblastomas, , it
is expected that in a near future molecular treatment that could be obtain more effective control
of disease progression will be used, resulting in an improved clinical course of these patients.
Over the years, with the increasing advances of molecular biology techniques, much informa‐
tion has been obtained on the role of p53 in carcinogenesis. Because of the critical role p53 plays
in a variety of cancers, a diversity of approaches have been undertaken to target p53 and its
altered signaling pathways. Different drugs targeting the p53 system in order to activate the
p53 pathway have been developed and several are now in clinical trials, and have shown
promising results.
Nomenclature
AT/RT Atypical Teratoid/ Rhabdoid Tumor
bFGF Basic fibroblast growth factor
BCL2 B-cell CLL/Lymphoma 2
BTSC Brain tumor stem cells
CSC Cancer stem cells
CDK4 Cyclin-dependent kinase 4
CDKN2A Cyclin-dependent kinase inhibitor 2A
CNS Central nervous systems
CHD5 Chromodomain helicase DNA binding protein 5
CPC Choroid plexus carcinomas
CPP Choroid plexus papilloma
CPT Choroid plexus tumors
EGF Epidermal growth factor
FISH Fluorescence in Situ Hybridization
GFAP Glial fibrillary acidic protein
GBM Glioblastoma
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IDH1 Isocitrate dehydrogenase 1 (NADP+)
IDH2 Iisocitrate dehydrogenase 2 (NADP+)
IHC Immunohistochemistry
IARC International Agency for Research on Cancer
LFS Li-Fraumeni syndromes
LFL Li-Fraumeni-like syndromes
LOH Loss of heterozygosity
MRT Malignant Rhabdoid Tumor
MDM2 MDM2 oncogene, E3 ubiquitin protein ligase
MDM4 Mdm4 p53 binding protein homolog
MB Medulloblastoma
MET Met proto-oncogene
MS-PCR Methylation-specific PCR
miRNA MicroRNAs
MYC v-myc avian myelocytomatosis viral oncogene homolog
HNSCC Head and Neck squamous cell carcinoma
NES Nuclear Exclusion Domain
NLS Nuclear Localization Domain
NSC Neural stem cell
NF1 Neurofibromin 1
P14ARF Cyclin-dependent kinase inhibitor 2A (encoding p14)
P19ARF Cyclin-dependent kinase inhibitor 2A (encoding p19)
p15 INK4b Cyclin-dependent kinase inhibitor 2A (encoding p15)
p16 INK4a Cyclin-dependent kinase inhibitor 2A (encoding p16)
PTCH1 Patched homolog 1
PNET Primitive neuroectodermal tumor
PTEN Phosphatase and tensin homolog
qRT-PCR Quantitative real-time PCR
RB1 Retinoblastoma 1
siRNA small interfering RNA
SMARCB1 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B
member 1
SSCP Single strand conformation polymorphism
SHH Sonic hedgehog
TMZ Temozolomide
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TP53 Tumor protein p53
TSC1 Tuberous Sclerosis 1
WHO World Health Organization
WT Wild-type
WNT Wingless
PXA Xanthoastrocytoma pleomorphic
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